Dragon Life Science Holdings Group, Inc.
NOHO · OTC
5/31/2023 | 2/28/2023 | 2/28/2022 | 11/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.00 | -0.00 | 0.06 |
| FCF Yield | 20.79% | 0.00% | 3.73% | -5.40% |
| EV / EBITDA | -1.97 | 3.79 | 0.31 | -23.93 |
| Quality | ||||
| ROIC | 7.83% | 7.25% | 3.20% | 11.69% |
| Gross Margin | 1.36% | -65.36% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.00 | – | 0.19 | 1.04 |
| Growth | ||||
| Revenue 3-Year CAGR | 152,635.01% | 119,923.14% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 0.00% | 123.91% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -1.96 | 2.63 | 0.13 | -4.52 |
| Interest Coverage | -3.77 | -2.68 | -0.24 | -262.36 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -15,892.29 | -6,722.61 | 0.00 | 0.00 |